{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:03:20Z","timestamp":1790532200647,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This report presents the inaugural case of Gaucher disease identified in Kashgar Prefecture, Xinjiang, the westernmost region of China. It emphasizes an analysis of the clinical characteristics, diagnostic challenges, and treatment strategies within the unique geographical, cultural, and ethnic contexts. The study aims to investigate potential associations between environmental factors, genetic backgrounds, and lifestyle in Kashgar Prefecture, as they relate to the diagnosis, treatment, and prognosis of Gaucher disease, with the goal of optimizing diagnostic and therapeutic approaches in similar regions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective analysis of the patient's clinical data, employing advanced diagnostic methods in conjunction with multidisciplinary collaboration. The data encompassed clinical symptoms, laboratory tests, imaging examinations, genetic testing, diagnostic procedures, and individualized treatment plans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 12-year-old female patient from Kashgar, Xinjiang, China, presented with chronic anemia, hepatosplenomegaly, thrombocytopenia, recurrentepistaxis, and osseous pain. She was diagnosed with Gaucher disease type I through genetic testing and enzymatic examination. This case represents the first reported instance of this condition in the Xinjiang region. Notably, it exhibited unique clinical features, including the age of onset, severity of symptoms, and potential regional complications. Treatment with high-dose ambroxol and imiglucerase significantly alleviated the patient's symptoms, and continuous follow-up was conducted to assess long-term efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report underscores the critical importance of early diagnosis and timely intervention in the management of Gaucher disease, particularly in regions with limited medical resources such as Kashgar. The successful diagnosis and treatment of this case have facilitated communication and cooperation between primary healthcare units and external medical institutions. This has further driven interactions in various aspects such as academic exchanges, teleconsultations, and medical assistance. In turn, this has provided a solid foundation for safeguarding patients\u2019 rights and improving medical services.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1530177","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:39:33Z","timestamp":1758526773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Clinical case analysis of gaucher disease management in a resource-limited setting: a single center experience from Kashigar, Xinjiang Uygur Autonomous Region, the Western China"],"prefix":"10.3389","volume":"13","author":[{"given":"Gulinuer","family":"Maimaititusvn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maierhaba","family":"Kulaixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abudouwaili","family":"Atawula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3760\/cma.j.cn112140-20210611-00494","article-title":"Expert consensus on diagnosis and treatment of pediatric gaucher disease (2021)","volume":"59","year":"2021","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B2","doi-asserted-by":"publisher","first-page":"104339","DOI":"10.1016\/j.ejmg.2021.104339","article-title":"Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: a sixteen year single-center experience","volume":"64","author":"Gumus","year":"2021","journal-title":"Eur J Med Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1053\/j.gastro.2010.04.021","article-title":"The US food and drug administration approves a new gaucher disease drug","volume":"138","author":"Lang","year":"2010","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3760\/cma.j.issn.0253-2727.2020.04.005","article-title":"Survey on the quality of life of patients with type I Gaucher disease receiving imiglucerase treatment","volume":"41","author":"Li","year":"2020","journal-title":"Zhonghua Xueyexue Zazhi"},{"key":"B5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 gaucher disease: an expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum Mutat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/blood.v112.11.4648.4648","article-title":"Diagnostic and disease management algorithms for gaucher disease: a guide for haematologists","volume":"112","author":"Mistry","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7754\/Clin.Lab.2022.220816","article-title":"Clinical characteristics and GBA gene mutation analysis of gaucher disease type I","volume":"69","author":"Zhang","year":"2023","journal-title":"Clin Lab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s004390050454","article-title":"Molecular analysis of Gaucher disease: distribution of eight mutations and the complete gene deletion in 27 patients from Germany","volume":"99","author":"le Coutre","year":"1997","journal-title":"Hum Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"0","DOI":"10.3389\/fneur.2022.907317","article-title":"Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic gaucher disease 2","volume":"13","author":"Aries","year":"2022","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.bcmd.2006.02.001","article-title":"Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations","volume":"36","author":"Wan","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bcmd.2016.10.026","article-title":"Clinical and molecular characteristics of patients with Gaucher disease in Southern China","volume":"68","author":"Feng","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.braindev.2018.06.006","article-title":"Genotypes and phenotypes in 20 Chinese patients with type 2 Gaucher disease","volume":"40","author":"Kang","year":"2018","journal-title":"Brain Dev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-141527","article-title":"High-risk population screening for Gaucher disease: final results and key learnings from an Italian multicenter observational study","volume":"136","author":"Motta","year":"2020","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2141.2011.08989.x","article-title":"The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable","volume":"157","author":"Berger","year":"2012","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.ymgmr.2019.100476","article-title":"Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejpn.2021.03.013","article-title":"Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings","volume":"32","author":"Ramad\u017ea","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41582-018-0053-4","article-title":"Fetal gene therapy could be feasible for neuronopathic Gaucher disease","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2319364","DOI":"10.1001\/jamanetworkopen.2023.19364","article-title":"Use of ambroxol as therapy for Gaucher disease","volume":"6","author":"Zhan","year":"2023","journal-title":"JAMA Network Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ajh.26131","article-title":"Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data","volume":"96","author":"Istaiti","year":"2021","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.fsi.2020.05.015","article-title":"Retraction notice to \u201cresidual papaya promoting the growth performance, antioxidant, nonspecific immunity of juvenile Tilapia mossambica\u201d [Fish Shellfish Immunol. 98 (2020) 605\u2013610]","volume":"111","author":"Wu","year":"2021","journal-title":"Fish Shellfish Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1515\/jpem-2018-0549","article-title":"Two siblings with Gaucher type 3c: different clinical presentations","volume":"32","author":"Karakoyun","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13006-022-00469-6","article-title":"Knowledge attitudes and practice of breastmilk expression and storage among working mothers with infants under six months of age in Kenya","volume":"17","author":"Edemba","year":"2022","journal-title":"Int Breastfeed J"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1530177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:39:35Z","timestamp":1758526775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1530177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":27,"alternative-id":["10.3389\/fped.2025.1530177"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1530177","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1530177"}}